Purpose/Background: Numerous health authority approvals of esketamine nasal spray,
combined with oral antidepressant, to treat depressive symptoms in adults with major …

Background Patients with major depressive disorder (MDD) having active suicidal ideation
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …

Objective: To compare esketamine to placebo, each in addition to standard-of-care
treatment, for rapidly reducing major depressive disorder symptoms, including suicidal …

Background Esketamine (ESK) nasal spray, taken with oral antidepressant therapy, is
approved for the treatment of depressive symptoms in adults with major depressive disorder …

Purpose The impact of benzodiazepines on the efficacy and safety of esketamine as a rapid-
acting antidepressant remains unclear. Materials and Methods Data from two identically …

Objective: The authors compared the efficacy of standard-of-care treatment plus intranasal
esketamine or placebo for rapid reduction of symptoms of major depression, including …

Background About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants and are considered to have treatment-resistant …

Objective: The authors compared the efficacy of standard-of-care treatment plus intranasal
esketamine or placebo for rapid reduction of symptoms of major depression, including …

Objective: About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants. This study compared the efficacy and safety of …

Objective: To evaluate long-term safety and efficacy of esketamine nasal spray plus a new
oral antidepressant (OAD) in patients with treatment-resistant depression (TRD). Methods …